HeadlineShine

Sun Pharma’s specialty portfolio, Organon deal to drive growth

Economic TimesSun Pharma’s specialty portfolio, Organon deal to drive growth
Image: Economic Times

Sun Pharmaceutical achieved notable revenue growth in the September quarter, driven by strong performance in India and specialty medicines. The company anticipates medium-term growth from therapies like Ilumya and ongoing innovative projects. Although…

Summary from Economic Times

Read the full story on Economic Times
React

Trending now

More business

See all →

Top stories in India

See all →